

Application of *Helicobacter pylori* antigen test to evaluate gastric mucosa specimens

Namiot A.^{1*}, Leszczyńska K.², Namiot DB.³, Chilewicz M.⁴, Bucki R.⁵, Kemon A.⁶, Namiot Z.⁷

¹. Department of Human Anatomy, Medical University of Białystok, Poland

². Department of Diagnostic Microbiology, Medical University of Białystok, Poland

³. Department of Prosthetic Dentistry, Medical University of Białystok, Poland

⁴. Department of Internal Medicine and Gastroenterology, District Hospital, Białystok, Poland

⁵. Department of Microbiological and Nanobiomedical Engineering, Medical University of Białystok, Poland; The Faculty of Human Sciences of the Jan Kochanowski University in Kielce, Poland

⁶. Department of General Pathomorphology, Medical University of Białystok, Poland

⁷. Department of Physiology, Medical University of Białystok, Poland; Institute for Medicine, State College of Computer Science and Business Administration, Łomża, Poland

ABSTRACT

Purpose: To investigate, whether the test documenting the presence of *Helicobacter pylori* (*H. pylori*) antigens in the gastric mucosa may be used as diagnostic test.

Materials and methods: Mucosal specimens taken from eighty-three patients during gastroscopic examination were subjected to rapid urease test (CLO test), histology, and *H. pylori* culture. The same biopsy specimens that had been evaluated in the CLO test or collected into the transport medium for bacterial culture were used to detect *H. pylori* antigens. An amplified immunoassay for the detection of *H. pylori* antigens in stool was used for gastric mucosa specimens. The sensitivity and specificity of the *H. pylori* antigen test were evaluated in relation to the results of each verifying test (CLO test, histology, culture) separately and to all 3 tests analysed together.

Results: The sensitivity and specificity of the *H. pylori* antigen test in relation to the CLO test, histological examination, and *H. pylori* culture were 85.4% and 90.5%, 76.1% and 83.4%, and 90.7% and 90.0% for specimens taken for the CLO test and 90.0% and 82.0%, 78.0% and 81.0%, and 93.0% and 88.0% for specimens taken for bacterial culture, respectively. The sensitivity and specificity of the antigen test in relation to all 3 verifying tests analysed together were 91.3% and 97.3% for specimens taken for the CLO test, and 91.7% and 97.1% for specimens taken for bacterial culture, respectively.

Conclusions: *H. pylori* antigen test in gastric mucosa specimens may be a sufficiently reliable source of information about stomach infection.

Key words: *Helicobacter pylori* antigens, immunoassay, gastric mucosa

*Corresponding author

Dr Andrzej Namiot

Department of Human Anatomy, Medical University of Białystok, 1 Kilińskiego St.
15-089 Białystok, Poland

Tel.: +48 85 87985661, Fax: +48 85 8795664

e-mail: anamiot@poczta.onet.pl

Received: 08.10.2014

Accepted: 14.11.2014

Progress in Health Sciences

Vol. 4(2) 2014 pp 52-57

© Medical University of Białystok, Poland

INTRODUCTION

For years, the urease tests [*Campylobacter*-like organism (CLO) test, urea breath test] have been the most commonly applied diagnostic test for *Helicobacter pylori* (*H. pylori*) infection. Their sensitivity and specificity can amount up to 90% [1-7]. This means that some patients have negative test result despite being infected, while others have a positive result when no infection exists. A false negative test result is found when the number of bacteria in the mucosal specimen is too small or their urease activity is too weak [1,8]. A false positive result of the urease test is most frequently associated with the presence of urease-positive bacteria other than *H. pylori* in the stomach; they usually originate from the oral cavity [9]. Such a phenomenon is most often observed in patient receiving long-term therapy with proton pump inhibitors [10,11]. Apart from the urease tests, there are a number of other methods used to diagnose stomach infection (histological examination, bacterial culture, molecular biology techniques) [2,3,12-19]. However, except for histological examination, other methods are not widely applied in clinical practice. In the last ten years, a test documenting the presence of bacterial antigens in the stool has been used for the diagnosis of *H. pylori* infection [7,20-22]. After being slightly adapted, this test has also found application in the evaluation of *H. pylori* infection of the oral cavity [23-26].

The aim of this study was to investigate whether the test for *H. pylori* antigens detection in stool may be used for detection of *H. pylori* antigens in biopsy specimens of the gastric mucosa.

MATERIALS AND METHODS

Study subjects

Eighty-three subjects, aged 20-79 years old, were included in the study (Table 1).

Table 1. Patient characteristics.

Age (years)	56.6 ± 13.9
Gender (M/F)	34 / 49
Smokers (%)	19 (22.9)
Drinkers (%)	18 (21.7)
Diagnosis	
Gastritis (%)	67 (80.7)
Peptic ulcer disease (%)	16 (19.3)

The inclusion criteria were good general condition (anamnesis, physical examination), no chronic or devastating diseases, no history of antibiotic therapy in the past month and no history of *H. pylori* eradication. The study was approved by the

Ethics Committee for Research on Humans and Animals of Medical University of Białystok. Written consent was obtained from all subjects before study entry.

Sample collection

During the gastroscopic examination eight biopsy specimens of the gastric mucosa from the prepyloric area and gastric body were taken, one for CLO test, one for bacterial culture, and two for histological examination from each site. Gastric infection with *H. pylori* was evaluated by CLO test prepared in the Physiology Department of the Medical University of Białystok, according to the method of Marshall et al. [27]. The sensitivity and specificity of the test in relation to histological examination, culture, and stool test were 84.3% and 88.4%, 87.5% and 83.5%, and 75.4% and 87.5%, respectively. The test result was defined as positive if its colour changed from orange to pink within 2 hours. The biopsy specimens for histological examination were processed according to a standard procedure [17]. To detect *H. pylori* antigens in the gastric mucosa, the same biopsy specimens that had earlier been evaluated in the CLO test or collected into the transport medium for bacterial culture were used.

Sample processing

The specimens designed for bacterial culture were placed into the transport medium (Portagerm *pylori*, bioMerieux, Marcy l'Etoile, France) and then after homogenisation in 100 µL of saline were inoculated on selective *Pylori* agar (bioMerieux) and non-selective Columbia agar enriched with 5% sheep blood (bioMerieux) [28]. The remaining sample volume was supplemented with 100 µL of sample diluent, included in the *H. pylori* antigen detecting set for stool (Amplified IDEIA™ Hp StAR™, Oxoid, Ely, UK). Similarly, the specimens subjected to the CLO test (positive results within 2 hours) were homogenized in 100 µL of saline supplemented with 100 µL of the diluents, included in the *H. pylori* antigen detection set. All samples were vortexed for 30 seconds and centrifuged for 5 minutes at 5000 rpm. Fifty µL of supernatant was sampled for further analysis.

H. pylori antigen test performance

The laboratory procedures were performed according to the manufacturer's protocol attached to the test for *H. pylori* antigens detection in stool specimens (Amplified IDEIA™ Hp StAR™, Oxoid, Ely, UK). In brief, 50 µL of supernatant of gastric mucosa suspension as well as horseradish peroxidase labelled monoclonal antibodies were added in one step to the microwells of microtitration plate coated

by the manufacturer with monoclonal antibodies specific for *H. pylori*. During incubation, *H. pylori* antigens present in a sample bound to the antibodies located on the microplate and horseradish peroxidase, forming a sandwich complex. The microwells were washed with phosphate buffer to remove unbound antibody conjugate and then tetramethylbenzidine was added. Bound horseradish peroxidase oxidized tetramethylbenzidine to a blue coloured product. The reaction was stopped with sulphuric acid which changed the colour from blue to yellow. The intensity of the colour was determined spectrophotometrically.

Statistical analysis

The sensitivity and specificity of the test detecting *H. pylori* antigens in the endoscopically taken specimens of gastric mucosa were evaluated in

relation to the results of each verifying test (CLO test, histological examination, culture), separately for the biopsy specimens used in the CLO test and those taken for culture. The calculation of sensitivity and specificity of the *H. pylori* antigen test was performed also in relation to 3 verifying tests analysed together. For this analysis, the result was defined as true positive, if at least one verifying test was positive, and false positive when all verifying tests were negative.

The result of the test was defined as true negative, if no more than one verifying test was positive and false negative, if more than one verifying test was positive. *H. pylori* antigen test sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy were calculated according to standard methods listed below.

$$\begin{aligned} \text{Sensitivity} &= \frac{\text{TP}}{\text{TP} + \text{FN}} & \text{Specificity} &= \frac{\text{TN}}{\text{TN} + \text{FP}} \\ \text{Positive predictive value} &= \frac{\text{TP}}{\text{TP} + \text{FP}} \\ \text{Negative predictive value} &= \frac{\text{TN}}{\text{TN} + \text{FN}} \\ \text{Accuracy} &= \frac{\text{TP} + \text{TN}}{\text{TP} + \text{FP} + \text{TN} + \text{FN}} \end{aligned}$$

(Legend: TP – true positive; FP – false positive; TN – true negative; FN – false negative)

RESULTS

In the group of 83 patients, we observed in only two subjects a difference in test results detecting *H. pylori* antigens in specimen’s primary taken for the culture and the CLO test; the result was twice positive for specimens taken for culture, with a concomitant negative result in specimens taken for the CLO test. The sensitivity and specificity of the antigen test in relation to the CLO test, histological examination and culture in biopsy specimens taken for CLO test were 85.4% and 90.5%, 76.1% and 83.4%, and 90.7% and 90.0%, respectively. For the specimens taken for culture, the sensitivity and specificity were 90.0%

and 82.0%, 78.0% and 81.0%, 93.0% and 88.0%, respectively.

The sensitivity and specificity of the antigen test in relation to all 3 verifying tests analysed together were, for the biopsy specimens taken for CLO test 91.3% and 97.3%, respectively, and for specimens taken for culture 91.7% and 97.1%, respectively (Table 3).

H. pylori antigens detection in gastric mucosa specimens was the most consistent with bacterial culture, and the least consistent with histological examination (Table 2).

Table 2. Sensitivity, specificity, positive and negative predictive values, and accuracy of *H. pylori* (*H.p.*) antigen test for gastric specimens versus the CLO test, histology and culture.

	<i>H.p.</i> antigens vs CLO test		<i>H.p.</i> antigens vs histology		<i>H.p.</i> antigens vs culture	
	A	B	A	B	A	B
Sensitivity	85.4	90.0	76.1	78.0	90.7	93.0
Specificity	90.5	82.0	83.4	81.0	90.0	88.0
Positive predictive value	89.7	81.4	85.4	83.7	90.7	93.0
Negative predictive values	86.4	90.0	75.5	75.0	90.0	87.0
Accuracy	87.9	85.5	79.5	79.5	90.3	90.4

A- CLO test samples; B- culture samples

Table 3. Sensitivity, specificity, positive and negative predictive values of *H. pylori* antigen test for gastric specimens versus 3 other diagnostic tests (CLO test, histology and culture).

	CLO test samples	Culture samples
Sensitivity	91.3	91.7
Specificity	97.3	97.1
Positive predictive values	97.7	97.8
Negative predictive values	90.0	89.5
Accuracy	94.0	94.0

DISCUSSION

The results of the current study indicate that the evaluation of *H. pylori* antigens in the endoscopically taken biopsy specimens is a relatively good diagnostic tool. However, the cost of a single examination in Poland is higher than a CLO test, but comparable with a histological examination, urea breath test or culture. The time required to obtain the test result is comparable with that of the CLO test or urea breath test, but shorter than histological examination or culture. The probability of obtaining a false positive result is small, as *H. pylori* belongs to dominating flora in the stomach and other bacteria present within the gastric mucosa should not be responsible for a positive test result. The probability

of obtaining a false negative result is not large as well, because the presence of as low as 100 *H. pylori* bacteria is sufficient to obtain a positive test result [23]; when two gastric mucosa biopsy specimens from the same patient were analysed together, the number of *H. pylori* bacteria was much larger than 100 [29]. One biopsy specimen of the gastric mucosa is probably sufficient to perform the test, however, in our study we used two specimens, one from the antrum and another one from the gastric body, because some patients participating in the study were under therapy with proton pump inhibitors and the distribution of bacteria in such patients is different than in untreated patients [4,18].

Since currently used methods for detecting stomach infection with *H. pylori* are encumbered with certain error, the new diagnostic techniques are still being developed and tested worldwide. The novelty of our study lies in the fact that the immunologic test formerly used for detection of *H. pylori* antigens in feces may be used more widely than the manufacturer designed. The evaluation of *H. pylori* antigens in gastric mucosal specimens, which were earlier used in a CLO test or taken for bacterial culture, enables the extension of diagnosis of *H. pylori* gastric infection without the need of having additional biopsy specimens. According to the results of current study, the evaluation of *H. pylori* antigens, both in the biopsy specimens taken for CLO test or culture, is encumbered with similar error. In the case of antigen detection in specimens taken exclusively for this aim, a small per cent decrease in sensitivity and specificity of this test in relation to verifying tests must be taken into account; this is suggested in our study on the base of slightly lower sensitivity and specificity of the *H. pylori* antigen test in relation to the histological examination. It cannot be ruled out that the test evaluating the presence of *H. pylori* antigens in the endoscopically taken specimens of the gastric mucosa might be used on equal terms with other tests diagnosing the stomach infection, both before and after eradication therapy. However, it is rather unlikely that it could compete with the urea breath test, CLO test or histological examination. We hope that in selected cases, detection of *H. pylori* antigens will answer the question whether increased urease activity in the gastric mucosa is related to the presence of *H. pylori* or other urease-positive bacteria.

CONCLUSIONS

Taking into account a relatively low accessibility to *H. pylori* bacteria culture from the biopsy specimens of the gastric mucosa (only selected microbiology laboratories in Poland provide such service), the test evaluating the presence of the

bacterial antigens may become a sufficiently reliable source of information concerning stomach infection.

Conflicts of interest

None declared

Funding

The study was supported by the Medical University of Białystok, grant no. 3 – 18628L

REFERENCES

1. Midolo P, Marshall BJ. Accurate diagnosis of *Helicobacter pylori*. Urease tests. Gastroenterol Clin North Am. 2000 Dec; 29(4): 871-8.
2. Logan RPH, Polson RJ, Misiewicz JJ, Karim NQ, Newell D, Johnson P, Wadsworth J, Walker MM, Baron JH. A simplified single sample ¹³C-urea breath test for *Helicobacter pylori*: comparison with histology, culture, and ELISA serology. Gut 1991 Dec; 32(12):1461-4.
3. Atherton C, Spiller C. The urea breath test for *Helicobacter pylori*. Gut 1994 Jun;35(6):723-5.
4. Rauws EA, Royen EA, Langenberg W, Woensel JV, Vrij AA, Tytgat GN. ¹⁴C-urea breath test in *C. pylori* gastritis. Gut 1989 Jun; 30(6):798-803.
5. Koumi A, Filippidis T, Leontara V, Makri L, Panos MZ. Detection of *Helicobacter pylori*: a faster urease test can save resources. World J Gastroenterol. 2011 Jan 21;17(3):349–53.
6. Hsu WH, Wang SSW, Kuo CH, Chen CY, Chang CW, Hu HM, Wang JY, Yang YC, Lin YC, Wang WM, Wu DC, Wu MT, Kuo FC. Dual specimens increase the diagnostic accuracy and reduce the reaction duration of rapid urease test. World J Gastroenterol. 2010 Jun21;16(23): 2926–30.
7. Perri F, Manes G, Neri M, Vaira D, Nardone G. *Helicobacter pylori* antigen stool test and ¹³C-urea breath test in patients after eradication treatments. Am J Gastroenterol. 2002 Nov; 97(11):2756-62.
8. Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of *Helicobacter pylori*: unique action selective for *H. pylori* cells. Antimicrob Agents Chemother. 1993 Apr;37(4):769-74.
9. Brandi G, Biavati B, Calabrese C, Granata M, Nannetti A, Mattarelli P, Di Febo G, Saccoccio G, Biasco G. Urease-positive bacteria other than *Helicobacter pylori* in human gastric juice and mucosa. Am J Gastroenterol. 2006 Aug;101(8): 1756-61.
10. Weston AP, Campbell DR, Hassanein RS, Cherian R, Dixon A, McGregor DH. Prospective, multivariate evaluation of CLO test performance. Am J Gastroenterol. 1997 Aug; 92(8):1310-15.
11. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, Tamura T, Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against *Helicobacter pylori*. Antimicrob Agents Chemother. 1991 Mar; 35(3):490-6.
12. Price AB. The Sydney System: histological division. J Gastroenterol Hepatol. 1991 May-Jun; 6(3): 209-22.
13. Loffeld RJ, Stobberingh E, Flendrig JA, Arends JW. *Helicobacter pylori* in gastric biopsy specimens. Comparison of culture, modified Giemsa stain, and immunohistochemistry. A retrospective study. J Pathol. 1991 Sep; 165(1):69-73.
14. Hammar M, Tyszkiewicz T, Wadstrom T, O'Toole PW. Rapid detection of *Helicobacter pylori* in gastric biopsy material by polymerase chain reaction. J Clin Microbiol. 1992 Jan; 30(1):54-8.
15. Assumpção MB, Martins LC, Melo Barbosa HP, Barile KAS, Almeida SS, Assumpção PP, Corvelo TCO. *Helicobacter pylori* in dental plaque and stomach of patients from Northern Brazil. World J Gastroenterol. 2010 Jun 28;16(24):3033–9.
16. Acosta N, Quiroga A, Delgado P, Bravo MM, Jaramillo C. *Helicobacter pylori* CagA protein polymorphisms and their lack of association with pathogenesis. World J Gastroenterol. 2010 Aug21; 16(31):3936–43.
17. Namiot A, Kemona A, Namiot Z. Smoking habit and gastritis histology. Adv Med Sci. 2007;52: 191-5.
18. Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of *Helicobacter pylori* during treatment with omeprazole. Gut 1995 Jan; 36(1):12-6.
19. Costa F, D'Elis MM. Management of *Helicobacter pylori* infection. Expert Rev Anti Infect Ther. 2010 Aug;8(8):887-92.
20. Trevisani L, Sartori S, Galvani F, Rossi MR, Ruina M, Chiamenti C, Caselli M. Evaluation of a new enzyme immunoassay for detecting *Helicobacter pylori* in feces: a prospective pilot study. Am J Gastroenterol. 1999 Jul; 94(7):1830-3.
21. Ito M, Tanaka S, Kim S, Tahara K, Kawamura Y, Sumii M, Takehara Y, Hayashi K, Okamoto E, Kunihiro M, Kunita T, Imagawa S, Takata S, Ueda H, Egi Y, Hiyama T, Ueno Y, Kitadai Y, Yoshihara M, Chayama K. A combination of the *Helicobacter pylori* stool antigen test and urea breath test is useful for clinical evaluation of eradication therapy: a multicenter study. J Gastroenterol Hepatol. 2005 Aug; 20(8):1241-5.

22. Perri F, Quitadamo M, Ricciardi R, Piepoli A, Cotugno R, Gentile A, Pilotto A, Andriulli A. Comparison of a monoclonal antigen stool test (Hp StAR) with the ¹³C-urea breath test in monitoring *Helicobacter pylori* eradication therapy. World J Gastroenterol. 2005 Oct 7;11(37):5878-81.
23. Leszczyńska K, Namiot DB, Namiot A, Chilewicz M, Leszczyńska JK, Bucki R, Kemon A, Namiot Z. Application of immunoassay for detection of *Helicobacter pylori* antigens in saliva (abstract). Helicobacter 2010;15:363.
24. Leszczyńska K, Namiot DB, Namiot Z, Leszczyńska JK, Jakoniuk P, Kemon A. Application of immunoassay for detection of *Helicobacter pylori* antigens in the dental plaque. Adv Med Sci. 2009;54(2):194-8.
25. Namiot DB, Leszczyńska K, Namiot Z, Chilewicz M, Bucki R, Kemon A. The occurrence of *Helicobacter pylori* antigens in dental plaque; an association with oral health status and oral hygiene practices. Adv Med Sci. 2010;55(2):167-71.
26. Namiot DB, Leszczyńska K, Namiot A, Leszczyńska UM, Bucki R, Milewski R, Namiot Z. The influence of oral health status and dental plaque removal practices on the occurrence of *Helicobacter pylori* antigens in saliva. Dent Med Probl. 2013;50(3):275-81.
27. Marshall BJ, Warren JR, Francis GJ, Langton SR, Goodwin CS, Blincow ED. Rapid urease test in the management of *Campylobacter pyloridis*-associated gastritis. Am J Gastroenterol. 1987 Mar; 82(3): 200-10.
28. Leszczyńska K, Namiot A, Namiot Z, Leszczyńska JK, Jakoniuk P, Chilewicz M, Namiot DB, Kemon A, Milewski R, Bucki R. Patient factors affecting culture of *Helicobacter pylori* isolated from gastric mucosal specimens. Adv Med Sci. 2010;55(2):161-6.
29. Atherton JC, Tham KT, Peek RM Jr, Cover TL, Blaser MJ. Density of *Helicobacter pylori* infection *in vivo* as assessed by quantitative culture and histology. J Infect Dis. 1996 Sep; 174 (3): 552-6.